Multiple Sclerosis
Conditions
Keywords
RRMS, CIS
Brief summary
This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon
Interventions
Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
DEVICEBetaconnect Autoinjector
Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged ≥ 18 years with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome * Patients on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician * Patients using or willing to use the BETACONNECT autoinjector for Betaferon application * Written informed consent
Exclusion criteria
* Patients receiving any other disease modifying drug * Contraindications of Betaferon described in the Summary of Product Characteristics * Patients participating in any other clinical or non-interventional study, evaluating MS therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compliance to therapy (%) | 12 months | Compliance (%) = ((expected # of treatment days during observation period - missed # of treatment days during observation period)/(expected # of treatment days during observation period))\*100 |
| Persistence of therapy (Yes or No) | 12 months | Persistence is defined as patients continuing (persisting) their medication (regardless of the frequency of intake) |
| Overall adherence to therapy (Yes or No) | 12 months | Patients will be defined as being adherent to therapy if they fulfill the following criteria: a. They have been at least 80% compliant, i.e. injected ≥80% of the expected Betaferon dosages and b. They have not dropped out of the study prior to the time of evaluation (i.e. they did not stop Betaferon treatment for any reason including switching to another medication prior to the time of evaluation). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adherence to Betaferon treatment is associated with EDSS change (Yes or No) | 12 months, 24 months | EDSS (Expanded Disability Status Scale) |
| Satisfaction with the BETACONNECT autoinjector, recorded by the patient questionnaire | Up to 24 months | — |
| Adherence to Betaferon treatment is associated with utilities of treatment, recorded by the EQ-5D quality of life questionnaire (Yes or No) | Up to 24 months | — |
| Adherence to Betaferon treatment is associated with: depression, health related quality of life, coping mechanisms, self-management mechanisms, social support, fatigue, and cognition. (Yes or No) | Up to 24 months | — |
| Adherence to Betaferon treatment is associated with number of relapses (Yes or No) | 12 months, 24 months | — |
Countries
Germany
Outcome results
None listed